Panel-based and hotspot testing may miss genomic variants—some of which may be actionable1,2
|DNA||RNA||Paired Tumor-Normal Match|
|Comprehensive genomic profiling
(Fixed panel DNA sequencing)
(whole-exome DNA sequencing + whole-transcriptome RNA sequencing)
Allows for comprehensive analysis of all protein-coding genes in a sample
Allows the identification of transcript variants and fusions that may be undetectable through conventional CGP tests, which only employ DNA analysis3
Detect more variants:
The OncoExTra test delivers the complete genomic story
Utilize patient-matched tumor-normal sequencing to further refine therapy selection
- Limit false positives by identifying and ruling out benign variants in a patient’s tumor sample vs normal blood sample3
- Reduce the overestimation of tumor mutational burden (TMB) calculations by excluding mutations also found in the normal sample3,4
Proven to reveal more clinically actionable information3
Actionable variants were found across many different types of solid tumors3
Across 1261 OncoExTra tests, more fusions were detected within RNA than DNA alone3 *
*Retrospective analysis of 1509 clinical reports, of which 1261 included both DNA and RNA profiling. OncoExTra RNA findings detected variants in 5.9% [75/1261] of samples vs 3.5% [44/1261] in DNA analysis.3
†Clinically actionable variants are defined as variants that are associated with available therapies or clinical trial enrollment for a specific somatic variant identified in a patient’s tumor.3
Understand the impact the test has on patients
Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®.‡
‡ OncoExtra was previously known as GEM ExTra.
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
GEM ExTra, OncoExTra; TMB, tumor mutational burden.